NYRADA INC (ASX:NYR) 2 “Our lead brain injury program candidate, NYR-BI03, is targeting a very large and growing market. There are no current FDAapproved therapies for TBI which is experienced by over 70 million people worldwide each year. The estimated annual healthcare cost of non-fatal TBIs is over US$40 billion in the US alone.”
RkJQdWJsaXNoZXIy MjE2NDg3